EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine



In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine



Antimicrobial Agents and ChemoTherapy 49(9): 3930-3932



Serial passage of human immunodeficiency virus type 1 in MT-2 cells in increasing concentrations of the d- and l-enantiomers of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (d4FC) resulted in the selection of viral variants with reverse transcriptase substitutions M184I or M184V for l-d4FC and I63L, K65R, K70N, K70E, or R172K for d-d4FC. Phenotypic analysis of site-directed mutants defined the role of these mutations in reducing susceptibility to l- or d-d4FC.

(PDF emailed within 0-6 h: $19.90)

Accession: 049316724

Download citation: RISBibTeXText

PMID: 16127074

DOI: 10.1128/AAC.49.9.3930-3932.2005



Related references

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. Journal of Medicinal Chemistry 39(9): 1757-1759, 1996

Design and synthesis of 2,3-dideoxy-2,3-didehydro-beta-L-cytidine and 2,3-dideoxy-2,3-didehydro-beta-L-5-fluorocytidine , two exceptionally potent inhibitors of human hepatitis B virus and potent inhibitors of human immunodeficiency virus in vitro. Journal of Medicinal Chemistry 39(9): 1757-1759, 1996

Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrobial Agents and ChemoTherapy 42(7): 1799-1804, 1998

Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochemical Pharmacology 47(2): 171-174, 1994

Antiviral activity of 2,3-dideoxy-beta-L-5-fluorocytidine and 2,3-dideoxy-beta-L-cytidine against hepatitis B virus and human immunodeficiency virus type 1 in-vitro. Biochemical Pharmacology 47(2): 171-174, 1994

Effects of the 5-triphosphate of beta-L-2,3-dideoxy-5-fluorocytidine on human immunodeficiency virus type 1 reverse transcriptase and human DNA-polymerases. Abstracts of Papers American Chemical Society 208(1-2): MEDI 40A, 1994

Anti-hepatitis B virus action and metabolism of 2-3-dideoxy-2,3-didehydro-beta-L -5-fluorocytidine. Proceedings of the American Association for Cancer Research Annual Meeting 39: 602, March, 1998

Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine. Antimicrobial Agents and ChemoTherapy 42(7): 1805-1810, 1998

Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrobial Agents and ChemoTherapy 45(4): 1065-1077, 2001

Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrobial Agents and ChemoTherapy 44(1): 111-122, 1999

Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine. Antimicrobial Agents and ChemoTherapy 44(5): 1127-1131, 2000

Interaction of beta-L-2,3-dideoxy-2,3-didehydro-5-fluorocytidine 5-triphosphate with HIV reverse transcriptase and human DNA polymerases Implication for HIV drug design. Antiviral Research 37(3): A39, March, 1998